Exousia Bio (LMMY) Accumulated Expenses (2022 - 2024)

Exousia Bio has disclosed Accumulated Expenses across 3 years of filings, most recently posting $1211.0 for Q3 2024.

• Accumulated Expenses for Q3 2024 came in at $1211.0, down 72.16% year-over-year; the trailing twelve-month figure through Aug 2024 was $1211.0 (down 72.16% YoY), and the FY2024 annual result was $11079.0, up 1716.23% from the prior year.
• Accumulated Expenses came in at $1211.0 for Q3 2024 at Exousia Bio, down from $11079.0 in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $11079.0 in Q2 2024 to a low of $333.0 in Q2 2022.
• The 3-year median for Accumulated Expenses is $4180.5 (2023), against an average of $4477.0.
• Peak annual rise in Accumulated Expenses reached 1716.23% in 2024, while the deepest fall reached 72.16% in 2024.
• Exousia Bio's Accumulated Expenses stood at $333.0 in 2022, then jumped by 2377.48% to $8250.0 in 2023, then plunged by 85.32% to $1211.0 in 2024.
• The last three Accumulated Expenses figures came in at $1211.0 (Q3 2024), $11079.0 (Q2 2024), and $5972.0 (Q1 2024), per Business Quant data.